Last month the FDA approved pembrolizumab (KEYTRUDA) for adult and pediatric patients with with metastatic or unresectable, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have...

HiPath™ Supports Pathologists with Advanced Image Analysis of PD-L1 Assays CARLSBAD, CA, May 11, 2017 -- Applied Spectral Imaging (ASI), a global leader of computer-assisted microscopy, introduces HiPath imaging and analysis of PD-L1...

Join Visiopharm at USCAP 2017 and learn about how we are transforming pathology! Come see demonstrations of Analysis of PD-L1 and CD Markers within the Tumor Micro-Environment Visualize and quantify biomarker expression with heatmaps...

Originally published by Simon Häger, Product Manager Sectra Digital Pathology Solution at Sectra.com.  It is hard to argue with any of the points raised here by Simon. No doubt image analysis will enable what we do to do it better. More...

New applications on the platform enable acceleration of breakthroughs in the fight against cancer. Baltimore, MD; San Diego, CA (PRWEB) October 24, 2016 -- Proscia Inc, the industry's leading provider of cloud solutions for digital...

Wednesday September 28th | 8 AM PDT | 11 AM EDT | 4 PM BST Presenters Dr. Tricia Cottrell, Johns Hopkins Medical School  Vlado Ovtcharov, Indica Labs PD-L1 expression in the tumor microenvironment can be both prognostic and predictive. ...